169 related articles for article (PubMed ID: 8309312)
1. Rapamycin: a novel immunosuppressive macrolide.
Sehgal SN; Molnar-Kimber K; Ocain TD; Weichman BM
Med Res Rev; 1994 Jan; 14(1):1-22. PubMed ID: 8309312
[No Abstract] [Full Text] [Related]
2. Immunosuppressive profile of rapamycin.
Sehgal SN
Ann N Y Acad Sci; 1993 Nov; 696():1-8. PubMed ID: 8109822
[No Abstract] [Full Text] [Related]
3. Rapamycin.
Carlson RP; Sehgal SN; Lewis AJ
Clin Exp Rheumatol; 1993; 11 Suppl 8():S129. PubMed ID: 8324938
[No Abstract] [Full Text] [Related]
4. Rapamycin: FK506's fraternal twin or distant cousin?
Morris RE
Immunol Today; 1991 May; 12(5):137-40. PubMed ID: 1715165
[TBL] [Abstract][Full Text] [Related]
5. Chemical modification of rapamycin: the discovery of SDZ RAD.
Sedrani R; Cottens S; Kallen J; Schuler W
Transplant Proc; 1998 Aug; 30(5):2192-4. PubMed ID: 9723437
[No Abstract] [Full Text] [Related]
6. Immunosuppressive drugs.
Collier SJ
Curr Opin Immunol; 1989-1990; 2(6):854-8. PubMed ID: 2484794
[No Abstract] [Full Text] [Related]
7. Rapamycin: in vitro profile of a new immunosuppressive macrolide.
Sehgal SN; Bansbach CC
Ann N Y Acad Sci; 1993 Jun; 685():58-67. PubMed ID: 8363266
[No Abstract] [Full Text] [Related]
8. Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide.
Brazelton TR; Morris RE
Curr Opin Immunol; 1996 Oct; 8(5):710-20. PubMed ID: 8902398
[TBL] [Abstract][Full Text] [Related]
9. Rapamune (Sirolimus, rapamycin): an overview and mechanism of action.
Sehgal SN
Ther Drug Monit; 1995 Dec; 17(6):660-5. PubMed ID: 8588237
[TBL] [Abstract][Full Text] [Related]
10. Rapamycin (sirolimus, rapamune).
Sehgal SN; Camardo JS; Scarola JA; Maida BT
Curr Opin Nephrol Hypertens; 1995 Nov; 4(6):482-7. PubMed ID: 8591055
[TBL] [Abstract][Full Text] [Related]
11. Pharmacology of rapamycin: a new immunosuppressive agent.
Chang JY; Sehgal SN
Br J Rheumatol; 1991; 30 Suppl 2():62-5. PubMed ID: 1993260
[No Abstract] [Full Text] [Related]
12. In vivo immunopharmacology of the macrolides FK 506 and rapamycin: toward the era of rational immunosuppressive drug discovery, development, and use.
Morris RE
Transplant Proc; 1991 Dec; 23(6):2722-4. PubMed ID: 1721257
[No Abstract] [Full Text] [Related]
13. [Immunosuppressive agents--advances of the developmental studies and the mode of action].
Ochiai T; Isono K; Gunji Y; Nagata M
Nihon Rinsho; 1991 Jun; 49(6):1436-41. PubMed ID: 1715926
[No Abstract] [Full Text] [Related]
14. Efficacy and mechanism of action of rapamycin in presensitized recipients of experimental allografts.
Chen H; Wu J; Xu D; Luo H; Daloze P
Transplant Proc; 1992 Oct; 24(5):1669-70. PubMed ID: 1412790
[No Abstract] [Full Text] [Related]
15. Effects of rapamycin in experimental organ allografting.
Ochiai T; Gunji Y; Nagata M; Komori A; Asano T; Isono K
Transplantation; 1993 Jul; 56(1):15-9. PubMed ID: 8333037
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of action of immunosuppressive agents: cyclosporin A, FK506, and rapamycin.
Bierer BE
Proc Assoc Am Physicians; 1995 Apr; 107(1):28-40. PubMed ID: 8630742
[No Abstract] [Full Text] [Related]
17. Effects of orally administered rapamycin in animal models of arthritis and other autoimmune diseases.
Carlson RP; Baeder WL; Caccese RG; Warner LM; Sehgal SN
Ann N Y Acad Sci; 1993 Jun; 685():86-113. PubMed ID: 8363289
[No Abstract] [Full Text] [Related]
18. Interaction of diltiazem and rapamycin on survival of rat cardiac allografts.
Dumont L; Chen H; Xu D; Daloze P
Ann N Y Acad Sci; 1993 Nov; 696():392-5. PubMed ID: 8109847
[No Abstract] [Full Text] [Related]
19. Effect of rapamycin on islet xenograft survival.
Lu X; Schuurman HJ; Borel JF
Transplant Proc; 1994 Jun; 26(3):1128-9. PubMed ID: 8029857
[No Abstract] [Full Text] [Related]
20. Revised NMR assignments for rapamycin.
McAlpine JB; Swanson SJ; Jackson M; Whittern DN
J Antibiot (Tokyo); 1991 Jun; 44(6):688-90. PubMed ID: 1712766
[No Abstract] [Full Text] [Related]
[Next] [New Search]
